Purpose Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in
advanced EGFR-mutant non–small-cell lung cancer (NSCLC), we tested adjuvant erlotinib …

Purpose Epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors have proven
efficacy in advanced non–small-cell lung cancer (NSCLC). We hypothesized that erlotinib …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …

Background Adjuvant chemotherapy after radical resection of stage IIIA non-small-cell lung
cancer (NSCLC) has quite poor outcomes. We aimed to investigate whether adjuvant …

Background: Patients with stage IV lung adenocarcinoma and epidermal growth factor
receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase …

Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …

Introduction Erlotinib (Tarceva®) has demonstrated a survival benefit in unselected patients
with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy. Because …

Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …

Abstract Lessons Learned The findings of this prospective, single‐arm, phase II study
showed that neoadjuvant erlotinib was well tolerated and might improve the radical …

7514 Background: EGFR mutant NSCLC is exquisitely sensitive to EGFR tyrosine kinase
inhibitors (TKIs). Retrospective data suggests adjuvant TKIs may improve outcomes. This …